Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

The Thalamocortical Circuit of Auditory Mismatch Negativity.

Lakatos P, O'Connell MN, Barczak A, McGinnis T, Neymotin S, Schroeder CE, Smiley JF, Javitt DC.

Biol Psychiatry. 2019 Nov 9. pii: S0006-3223(19)31851-7. doi: 10.1016/j.biopsych.2019.10.029. [Epub ahead of print]

2.

The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures.

Kraus MS, Gold JM, Barch DM, Walker TM, Chun CA, Buchanan RW, Csernansky JG, Goff DC, Green MF, Jarskog LF, Javitt DC, Kimhy D, Lieberman JA, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, Kern RS, McMahon RP, Robinson J, Marder SR, Keefe RSE.

Schizophr Res Cogn. 2019 Oct 31;19:100161. doi: 10.1016/j.scog.2019.100161. eCollection 2020 Mar.

3.

Neural and functional correlates of impaired reading ability in schizophrenia.

Dondé C, Martinez A, Sehatpour P, Patel GH, Kraut R, Kantrowitz JT, Javitt DC.

Sci Rep. 2019 Nov 5;9(1):16022. doi: 10.1038/s41598-019-52669-6.

4.

Bimodal distribution of tone-matching deficits indicates discrete pathophysiological entities within the syndrome of schizophrenia.

Dondé C, Martínez A, Kantrowitz JT, Silipo G, Dias EC, Patel GH, Sanchez-Peña J, Corcoran CM, Medalia A, Saperstein A, Vail B, Javitt DC.

Transl Psychiatry. 2019 Sep 6;9(1):221. doi: 10.1038/s41398-019-0557-8.

5.

Differential Patterns of Visual Sensory Alteration Underlying Face Emotion Recognition Impairment and Motion Perception Deficits in Schizophrenia and Autism Spectrum Disorder.

Martínez A, Tobe R, Dias EC, Ardekani BA, Veenstra-VanderWeele J, Patel G, Breland M, Lieval A, Silipo G, Javitt DC.

Biol Psychiatry. 2019 Oct 1;86(7):557-567. doi: 10.1016/j.biopsych.2019.05.016. Epub 2019 May 29.

PMID:
31301757
6.

Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene.

Bodkin JA, Coleman MJ, Godfrey LJ, Carvalho CMB, Morgan CJ, Suckow RF, Anderson T, Öngür D, Kaufman MJ, Lewandowski KE, Siegel AJ, Waldstreicher E, Grochowski CM, Javitt DC, Rujescu D, Hebbring S, Weinshilboum R, Rodriguez SB, Kirchhoff C, Visscher T, Vuckovic A, Fialkowski A, McCarthy S, Malhotra D, Sebat J, Goff DC, Hudson JI, Lupski JR, Coyle JT, Rudolph U, Levy DL.

Biol Psychiatry. 2019 Oct 1;86(7):523-535. doi: 10.1016/j.biopsych.2019.04.031. Epub 2019 May 9.

PMID:
31279534
7.

Are basic auditory processes involved in source-monitoring deficits in patients with schizophrenia?

Dondé C, Mondino M, Leitman DI, Javitt DC, Suaud-Chagny MF, D'Amato T, Brunelin J, Haesebaert F.

Schizophr Res. 2019 Aug;210:135-142. doi: 10.1016/j.schres.2019.05.034. Epub 2019 Jun 5.

PMID:
31176535
8.

A century of sensory processing dysfunction in schizophrenia.

Dondé C, Avissar M, Weber MM, Javitt DC.

Eur Psychiatry. 2019 Jun;59:77-79. doi: 10.1016/j.eurpsy.2019.04.006. Epub 2019 May 10. No abstract available.

PMID:
31082567
9.

Significant improvement in treatment resistant auditory verbal hallucinations after 5 days of double-blind, randomized, sham controlled, fronto-temporal, transcranial direct current stimulation (tDCS): A replication/extension study.

Kantrowitz JT, Sehatpour P, Avissar M, Horga G, Gwak A, Hoptman MJ, Beggel O, Girgis RR, Vail B, Silipo G, Carlson M, Javitt DC.

Brain Stimul. 2019 Jul - Aug;12(4):981-991. doi: 10.1016/j.brs.2019.03.003. Epub 2019 Mar 5.

PMID:
30922713
10.

Resting state functional connectivity predictors of treatment response to electroconvulsive therapy in depression.

Moreno-Ortega M, Prudic J, Rowny S, Patel GH, Kangarlu A, Lee S, Grinband J, Palomo T, Perera T, Glasser MF, Javitt DC.

Sci Rep. 2019 Mar 25;9(1):5071. doi: 10.1038/s41598-019-41175-4.

11.

Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study.

Girgis RR, Baker S, Mao X, Gil R, Javitt DC, Kantrowitz JT, Gu M, Spielman DM, Ojeil N, Xu X, Abi-Dargham A, Shungu DC, Kegeles LS.

Psychiatry Res. 2019 May;275:78-85. doi: 10.1016/j.psychres.2019.03.018. Epub 2019 Mar 12.

PMID:
30884334
12.

A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms.

Fleming LM, Javitt DC, Carter CS, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman J, Krystal JH, Corlett PR.

Neuroimage Clin. 2019;22:101739. doi: 10.1016/j.nicl.2019.101739. Epub 2019 Feb 28.

13.

Impact of baseline early auditory processing on response to cognitive remediation for schizophrenia.

Medalia A, Saperstein AM, Qian M, Javitt DC.

Schizophr Res. 2019 Jun;208:397-405. doi: 10.1016/j.schres.2019.01.012. Epub 2019 Jan 18.

PMID:
30665714
14.

Hierarchical deficits in auditory information processing in schizophrenia.

Dondé C, Silipo G, Dias EC, Javitt DC.

Schizophr Res. 2019 Apr;206:135-141. doi: 10.1016/j.schres.2018.12.001. Epub 2018 Dec 12.

PMID:
30551982
15.

Impaired Motion Processing in Schizophrenia and the Attenuated Psychosis Syndrome: Etiological and Clinical Implications.

Martínez A, Gaspar PA, Hillyard SA, Andersen SK, Lopez-Calderon J, Corcoran CM, Javitt DC.

Am J Psychiatry. 2018 Dec 1;175(12):1243-1254. doi: 10.1176/appi.ajp.2018.18010072. Epub 2018 Oct 3.

16.

Neurofilament light interaction with GluN1 modulates neurotransmission and schizophrenia-associated behaviors.

Yuan A, Veeranna, Sershen H, Basavarajappa BS, Smiley JF, Hashim A, Bleiwas C, Berg M, Guifoyle DN, Subbanna S, Darji S, Kumar A, Rao MV, Wilson DA, Julien JP, Javitt DC, Nixon RA.

Transl Psychiatry. 2018 Aug 24;8(1):167. doi: 10.1038/s41398-018-0194-7.

17.

The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review.

Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA.

J Psychiatr Res. 2019 Jan;108:57-83. doi: 10.1016/j.jpsychires.2018.07.006. Epub 2018 Jul 21. Review.

PMID:
30055853
18.

Sensory and cross-network contributions to response inhibition in patients with schizophrenia.

Hoptman MJ, Parker EM, Nair-Collins S, Dias EC, Ross ME, DiCostanzo JN, Sehatpour P, Javitt DC.

Neuroimage Clin. 2018 Jan 6;18:31-39. doi: 10.1016/j.nicl.2018.01.001. eCollection 2018.

19.

Seeing the World as it is: Mimicking Veridical Motion Perception in Schizophrenia Using Non-invasive Brain Stimulation in Healthy Participants.

Pobric G, Hulleman J, Lavidor M, Silipo G, Rohrig S, Dias E, Javitt DC.

Brain Topogr. 2018 Sep;31(5):827-837. doi: 10.1007/s10548-018-0639-6. Epub 2018 Mar 7.

20.

Excitatory Amino Acids in Schizophrenia: Both What You Have, and What You Do With Them.

Javitt DC.

Biol Psychiatry. 2018 Mar 15;83(6):470-472. doi: 10.1016/j.biopsych.2018.01.006. No abstract available.

PMID:
29429500
21.

Prediction of psychosis across protocols and risk cohorts using automated language analysis.

Corcoran CM, Carrillo F, Fernández-Slezak D, Bedi G, Klim C, Javitt DC, Bearden CE, Cecchi GA.

World Psychiatry. 2018 Feb;17(1):67-75. doi: 10.1002/wps.20491.

22.

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.

Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Corlett PR, Rothman DL, Mason G, Qiu M, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman JA.

JAMA Psychiatry. 2018 Jan 1;75(1):11-19. doi: 10.1001/jamapsychiatry.2017.3572.

23.

Developmental trajectory of mismatch negativity and visual event-related potentials in healthy controls: Implications for neurodevelopmental vs. neurodegenerative models of schizophrenia.

Corcoran CM, Stoops A, Lee M, Martinez A, Sehatpour P, Dias EC, Javitt DC.

Schizophr Res. 2018 Jan;191:101-108. doi: 10.1016/j.schres.2017.09.047. Epub 2017 Oct 13.

24.

Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.

Lee M, Balla A, Sershen H, Sehatpour P, Lakatos P, Javitt DC.

Neuropsychopharmacology. 2018 Feb;43(3):571-582. doi: 10.1038/npp.2017.176. Epub 2017 Aug 17.

25.

A tale of two sites: Differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia.

Lee M, Sehatpour P, Dias EC, Silipo GS, Kantrowitz JT, Martinez AM, Javitt DC.

Schizophr Res. 2018 Jan;191:10-17. doi: 10.1016/j.schres.2017.07.032. Epub 2017 Aug 2.

PMID:
28779851
26.

Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia.

Avissar M, Xie S, Vail B, Lopez-Calderon J, Wang Y, Javitt DC.

Schizophr Res. 2018 Jan;191:25-34. doi: 10.1016/j.schres.2017.07.009. Epub 2017 Jul 11.

27.

Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia.

Javitt DC, Lee M, Kantrowitz JT, Martinez A.

Schizophr Res. 2018 Jan;191:51-60. doi: 10.1016/j.schres.2017.06.023. Epub 2017 Jun 28. Review.

PMID:
28666633
28.

Neurophysiological Effects of Bitopertin in Schizophrenia.

Kantrowitz JT, Nolan KA, Epstein ML, Lehrfeld N, Shope C, Petkova E, Javitt DC.

J Clin Psychopharmacol. 2017 Aug;37(4):447-451. doi: 10.1097/JCP.0000000000000722.

29.

Mismatch negativity (MMN) to spatial deviants and behavioral spatial discrimination ability in the etiology of auditory verbal hallucinations and thought disorder in schizophrenia.

Perrin MA, Kantrowitz JT, Silipo G, Dias E, Jabado O, Javitt DC.

Schizophr Res. 2018 Jan;191:140-147. doi: 10.1016/j.schres.2017.05.012. Epub 2017 May 19.

PMID:
28532686
30.

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.

Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, Petkova E, Silipo G, Javitt DC.

Schizophr Res. 2018 Jan;191:70-79. doi: 10.1016/j.schres.2017.02.027. Epub 2017 Mar 18.

PMID:
28318835
31.

Neural mechanisms of mismatch negativity dysfunction in schizophrenia.

Lee M, Sehatpour P, Hoptman MJ, Lakatos P, Dias EC, Kantrowitz JT, Martinez AM, Javitt DC.

Mol Psychiatry. 2017 Nov;22(11):1585-1593. doi: 10.1038/mp.2017.3. Epub 2017 Feb 7.

32.

Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.

Kantrowitz JT, Epstein ML, Beggel O, Rohrig S, Lehrfeld JM, Revheim N, Lehrfeld NP, Reep J, Parker E, Silipo G, Ahissar M, Javitt DC.

Brain. 2016 Dec;139(Pt 12):3281-3295.

33.

Bitopertin in schizophrenia: glass half full?

Javitt DC.

Lancet Psychiatry. 2016 Dec;3(12):1092-1093. doi: 10.1016/S2215-0366(16)30354-6. Epub 2016 Nov 2. No abstract available.

PMID:
27816569
34.

Global dynamics of selective attention and its lapses in primary auditory cortex.

Lakatos P, Barczak A, Neymotin SA, McGinnis T, Ross D, Javitt DC, O'Connell MN.

Nat Neurosci. 2016 Dec;19(12):1707-1717. doi: 10.1038/nn.4386. Epub 2016 Sep 12.

35.

Loneliness in schizophrenia and its possible correlates. An exploratory study.

Trémeau F, Antonius D, Malaspina D, Goff DC, Javitt DC.

Psychiatry Res. 2016 Dec 30;246:211-217. doi: 10.1016/j.psychres.2016.09.043. Epub 2016 Sep 26.

PMID:
27721059
36.

Pupillometer-based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis.

Choi J, Corcoran CM, Fiszdon JM, Stevens M, Javitt DC, Deasy M, Haber LC, Dewberry MJ, Pearlson GD.

Psychiatr Rehabil J. 2017 Mar;40(1):33-42. doi: 10.1037/prj0000217. Epub 2016 Aug 25.

37.

Targeting glutamate to treat schizophrenia: lessons from recent clinical studies.

Beck K, Javitt DC, Howes OD.

Psychopharmacology (Berl). 2016 Jul;233(13):2425-8. doi: 10.1007/s00213-016-4318-6. Epub 2016 May 23. No abstract available.

PMID:
27212398
38.

Fractal Dimension Analysis of Subcortical Gray Matter Structures in Schizophrenia.

Zhao G, Denisova K, Sehatpour P, Long J, Gui W, Qiao J, Javitt DC, Wang Z.

PLoS One. 2016 May 13;11(5):e0155415. doi: 10.1371/journal.pone.0155415. eCollection 2016. Erratum in: PLoS One. 2016 Oct 11;11(10 ):e0164910.

39.

Differential profiles in auditory social cognition deficits between adults with autism and schizophrenia spectrum disorders: A preliminary analysis.

Tobe RH, Corcoran CM, Breland M, MacKay-Brandt A, Klim C, Colcombe SJ, Leventhal BL, Javitt DC.

J Psychiatr Res. 2016 Aug;79:21-27. doi: 10.1016/j.jpsychires.2016.04.005. Epub 2016 Apr 16.

PMID:
27131617
40.

What can the study of first impressions tell us about attitudinal ambivalence and paranoia in schizophrenia?

Trémeau F, Antonius D, Todorov A, Rebani Y, Ferrari K, Lee SH, Calderone D, Nolan KA, Butler P, Malaspina D, Javitt DC.

Psychiatry Res. 2016 Apr 30;238:86-92. doi: 10.1016/j.psychres.2016.02.014. Epub 2016 Feb 13.

PMID:
27086216
41.

Biotypes in Psychosis: Has the RDoC Era Arrived?

Javitt DC.

Am J Psychiatry. 2016 Apr 1;173(4):313-4. doi: 10.1176/appi.ajp.2016.16020140. No abstract available.

PMID:
27035527
42.

Applying Transcranial Magnetic Stimulation (TMS) Over the Dorsal Visual Pathway Induces Schizophrenia-like Disruption of Perceptual Closure.

Amiaz R, Vainiger D, Gershon AA, Weiser M, Lavidor M, Javitt DC.

Brain Topogr. 2016 Jul;29(4):552-60. doi: 10.1007/s10548-016-0487-1. Epub 2016 Mar 28.

PMID:
27021230
43.

Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.

Sershen H, Hashim A, Dunlop DS, Suckow RF, Cooper TB, Javitt DC.

Neurochem Res. 2016 Feb;41(1-2):398-408. doi: 10.1007/s11064-016-1838-8. Epub 2016 Feb 8.

44.

Complementary fMRI and EEG evidence for more efficient neural processing of rhythmic vs. unpredictably timed sounds.

van Atteveldt N, Musacchia G, Zion-Golumbic E, Sehatpour P, Javitt DC, Schroeder C.

Front Psychol. 2015 Oct 27;6:1663. doi: 10.3389/fpsyg.2015.01663. eCollection 2015.

45.

Replacing DSM Categorical Analyses With Dimensional Analyses in Psychiatry Research: The Research Domain Criteria Initiative.

Yee CM, Javitt DC, Miller GA.

JAMA Psychiatry. 2015 Dec;72(12):1159-60. doi: 10.1001/jamapsychiatry.2015.1900. No abstract available.

PMID:
26559005
46.

Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia.

Kantrowitz JT, Hoptman MJ, Leitman DI, Moreno-Ortega M, Lehrfeld JM, Dias E, Sehatpour P, Laukka P, Silipo G, Javitt DC.

J Neurosci. 2015 Nov 4;35(44):14909-21. doi: 10.1523/JNEUROSCI.4603-14.2015.

47.

Implicit emotion perception in schizophrenia.

Trémeau F, Antonius D, Todorov A, Rebani Y, Ferrari K, Lee SH, Calderone D, Nolan KA, Butler P, Malaspina D, Javitt DC.

J Psychiatr Res. 2015 Dec;71:112-9. doi: 10.1016/j.jpsychires.2015.10.001. Epub 2015 Oct 9.

PMID:
26473695
48.

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.

Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, Silipo G, Javitt DC.

Lancet Psychiatry. 2015 May;2(5):403-412. doi: 10.1016/S2215-0366(15)00098-X. Epub 2015 Apr 28.

PMID:
26360284
49.

Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.

Javitt DC.

Curr Treat Options Psychiatry. 2015 Jun;1(2):107-120. No abstract available.

50.

Auditory dysfunction in schizophrenia: integrating clinical and basic features.

Javitt DC, Sweet RA.

Nat Rev Neurosci. 2015 Sep;16(9):535-50. doi: 10.1038/nrn4002. Review.

Supplemental Content

Loading ...
Support Center